MX2017012708A - Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo. - Google Patents
Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo.Info
- Publication number
- MX2017012708A MX2017012708A MX2017012708A MX2017012708A MX2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A
- Authority
- MX
- Mexico
- Prior art keywords
- ester
- dry eye
- therapeutic agent
- methenolone
- nandrolone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un objetivo de la presente invención es proporcionar un agente terapéutico para ojo seco novedoso que demuestre efectos terapéuticos para ojo seco superiores, y desde el punto de vista de la carga de administración de fármaco del paciente, sea capaz de demostrar un efecto medicinal durante un periodo largo de tiempo en tejido de glándula lacrimal después de la administración del mismo. Un agente terapéutico para ojo seco que comprende nandrolona o un éster del mismo o metenolona o un éster del mismo es terapéuticamente efectivo sobre el ojo seco ya que incrementa la cantidad de lágrima lipocalina (TL) en lágrimas, y los efectos medicinales se pueden demostrar durante un periodo largo de tiempo en tejido de glándula lacrimal al administrar un agente terapéutico para ojo seco que comprende nandrolona o un éster del mismo o metenolona o un éster del mismo a la piel del párpado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015076889 | 2015-04-03 | ||
| PCT/JP2016/060927 WO2016159350A1 (ja) | 2015-04-03 | 2016-04-01 | ナンドロロンまたはそのエステル、メテノロンまたはそのエステルを有効成分とするドライアイ治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012708A true MX2017012708A (es) | 2018-01-09 |
Family
ID=57005003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012708A MX2017012708A (es) | 2015-04-03 | 2016-04-01 | Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180071313A1 (es) |
| EP (1) | EP3278804A4 (es) |
| JP (1) | JP2016196453A (es) |
| KR (1) | KR20170132319A (es) |
| CN (1) | CN107427525A (es) |
| AU (1) | AU2016240948A1 (es) |
| BR (1) | BR112017021044A2 (es) |
| CA (1) | CA2981691A1 (es) |
| EA (1) | EA201792206A1 (es) |
| HK (2) | HK1243349A1 (es) |
| IL (1) | IL254828A0 (es) |
| MX (1) | MX2017012708A (es) |
| PH (1) | PH12017501796A1 (es) |
| SG (2) | SG10201908566YA (es) |
| TW (1) | TW201642868A (es) |
| WO (1) | WO2016159350A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07508716A (ja) * | 1992-04-21 | 1995-09-28 | ザ スキーペンズ アイ リサーチ インスティテュート，インコーポレイテッド | シェーグレン症候群における眼のアンドロゲン療法 |
| US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| US20050159361A1 (en) * | 2002-03-11 | 2005-07-21 | Takahito Hara | Remedies for sex hormone-dependent disease |
| EP1858522A4 (en) * | 2005-03-02 | 2008-07-16 | Pharmaceutical Inc Nascent | PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS |
| DE102006003512A1 (de) * | 2006-01-24 | 2007-08-02 | Bayer Schering Pharma Ag | Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| RU2510274C2 (ru) * | 2008-05-07 | 2014-03-27 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Терапевтическое восстановление и усиление увлажнения поверхности глаза |
-
2016
- 2016-04-01 MX MX2017012708A patent/MX2017012708A/es unknown
- 2016-04-01 JP JP2016073886A patent/JP2016196453A/ja active Pending
- 2016-04-01 WO PCT/JP2016/060927 patent/WO2016159350A1/ja active Application Filing
- 2016-04-01 US US15/563,108 patent/US20180071313A1/en not_active Abandoned
- 2016-04-01 AU AU2016240948A patent/AU2016240948A1/en not_active Abandoned
- 2016-04-01 CN CN201680021224.8A patent/CN107427525A/zh active Pending
- 2016-04-01 EP EP16773230.4A patent/EP3278804A4/en not_active Withdrawn
- 2016-04-01 BR BR112017021044-4A patent/BR112017021044A2/pt not_active Application Discontinuation
- 2016-04-01 SG SG10201908566Y patent/SG10201908566YA/en unknown
- 2016-04-01 TW TW105110451A patent/TW201642868A/zh unknown
- 2016-04-01 CA CA2981691A patent/CA2981691A1/en not_active Abandoned
- 2016-04-01 SG SG11201707804YA patent/SG11201707804YA/en unknown
- 2016-04-01 KR KR1020177031727A patent/KR20170132319A/ko unknown
- 2016-04-01 EA EA201792206A patent/EA201792206A1/ru unknown
-
2017
- 2017-09-29 PH PH12017501796A patent/PH12017501796A1/en unknown
- 2017-10-01 IL IL254828A patent/IL254828A0/en unknown
-
2018
- 2018-03-01 HK HK18102957.7A patent/HK1243349A1/zh unknown
- 2018-05-09 HK HK18106027.4A patent/HK1246644A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017501796A1 (en) | 2018-04-02 |
| KR20170132319A (ko) | 2017-12-01 |
| CA2981691A1 (en) | 2016-10-06 |
| EP3278804A4 (en) | 2019-02-27 |
| HK1246644A1 (zh) | 2018-09-14 |
| TW201642868A (zh) | 2016-12-16 |
| EA201792206A1 (ru) | 2018-02-28 |
| HK1243349A1 (zh) | 2018-07-13 |
| EP3278804A1 (en) | 2018-02-07 |
| JP2016196453A (ja) | 2016-11-24 |
| BR112017021044A2 (pt) | 2018-07-24 |
| AU2016240948A1 (en) | 2017-11-16 |
| CN107427525A (zh) | 2017-12-01 |
| IL254828A0 (en) | 2017-12-31 |
| WO2016159350A1 (ja) | 2016-10-06 |
| SG11201707804YA (en) | 2017-10-30 |
| US20180071313A1 (en) | 2018-03-15 |
| SG10201908566YA (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| PH12019500423A1 (en) | Pharmaceutical composition | |
| WO2015095772A3 (en) | Formulations and methods for targeted ocular delivery of therapeutic agents | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| MX2016010899A (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| MX2016014699A (es) | (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina. | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| PH12017501796A1 (en) | Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient | |
| MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. |